Last reviewed · How we verify
Clindamycin + BPO
Clindamycin + BPO is a Topical antibiotic + oxidizing agent combination Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for Acne vulgaris (inflammatory and comedonal).
Clindamycin kills acne-causing bacteria while benzoyl peroxide reduces sebum production and provides antimicrobial activity, together reducing inflammatory and comedonal acne.
Clindamycin, a small molecule bacterial 70S ribosome inhibitor, is used in combination with benzoyl peroxide to treat acne vulgaris. This combination is available in a 1.2%/3.75% gel formulation, such as Onexton, which has been studied in clinical trials for its effectiveness in treating acne.
At a glance
| Generic name | Clindamycin + BPO |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Topical antibiotic + oxidizing agent combination |
| Target | Bacterial 50S ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, effectively killing Cutibacterium acnes. Benzoyl peroxide is an oxidizing agent that generates reactive oxygen species to kill bacteria and also helps reduce sebum production and comedone formation. The combination provides synergistic antibacterial and anti-inflammatory effects on acne lesions.
Approved indications
- Acne vulgaris (inflammatory and comedonal)
Common side effects
- Skin irritation
- Dryness
- Erythema
- Peeling
- Contact dermatitis
Key clinical trials
- Experience With Topical Acne Treatment (EARLY_PHASE1)
- Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel (PHASE2)
- Cutibacterium Dermal Colonization: Implications for Total Hip Arthroplasty (PHASE4)
- Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris (PHASE3)
- Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris (PHASE3)
- A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris (PHASE1)
- Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects (PHASE3)
- Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clindamycin + BPO CI brief — competitive landscape report
- Clindamycin + BPO updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Clindamycin + BPO
What is Clindamycin + BPO?
How does Clindamycin + BPO work?
What is Clindamycin + BPO used for?
Who makes Clindamycin + BPO?
What drug class is Clindamycin + BPO in?
What development phase is Clindamycin + BPO in?
What are the side effects of Clindamycin + BPO?
What does Clindamycin + BPO target?
Related
- Drug class: All Topical antibiotic + oxidizing agent combination drugs
- Target: All drugs targeting Bacterial 50S ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Acne vulgaris (inflammatory and comedonal)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing